- Ongoing, recruitingPhase II and Phase III (Integrated)
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
This study is testing a new medicine, spesolimab, for people with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it helps reduce HS symptoms and if it's safe. Some people will get the new medicine, while others will get a dummy medicine (placebo).
For: Hidradenitis suppurativaCzechia · Germany · Portugal - Ongoing, recruitingPhase II and Phase III (Integrated)
Evasayil TM: A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome
This study is testing a new medicine, spesolimab, for Netherton syndrome. It's a trial where some people get the medicine and others get a dummy treatment (placebo) to see how well spesolimab works and if it's safe. We're looking at how it improves skin symptoms and overall well-being.
For: Netherton syndrome (NS)Spain · Belgium · Bulgaria - Ongoing, recruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
For: Hidradenitis Suppurativa (HS)Spain · Slovakia · France